Baxfendy (Baxdrostat) FDA Approval for Hypertension
Review the May 2026 FDA approval of Baxfendy (baxdrostat), analyzing its mechanism as an aldosterone synthase inhibitor for uncontrolled hypertension.
Back to Articles
Articles tagged with “resistant-hypertension”